Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "innovators"

160 News Found

Hikal posts FY23 PAT at Rs. 36 Cr
News | May 30, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22


Aurisco expands Oligonucleotide capacity
News | April 24, 2023

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.


Agilent announces digital pathology workflow solution
Digitisation | March 13, 2023

Agilent announces digital pathology workflow solution

Open, scalable, end-to-end solution to improve diagnostic quality and efficiency


Build a sustainable healthcare and lifesciences industry, say Experts
Healthcare | March 11, 2023

Build a sustainable healthcare and lifesciences industry, say Experts

Time to combine innovation, access and technology to deliver positive patient outcomes


Evonik partners with AMSilk to manufacture sustainable silk proteins
News | March 07, 2023

Evonik partners with AMSilk to manufacture sustainable silk proteins

Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials


Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
News | March 03, 2023

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event


Themis Medicare launches Lenzetto for treatment of menopausal symptoms
News | January 04, 2023

Themis Medicare launches Lenzetto for treatment of menopausal symptoms

It ensures sufficient serum estradiol levels to alleviate menopausal symptoms


Advent International to acquire a significant stake in Suven Pharmaceuticals
News | December 26, 2022

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.